MaxCyte MXCT Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Assay And Other Service Revenue | $482K-20.9% | $609K-6.3% | $650K+110% | $310K-21.9% | $397K— | |
| License | $5.53M+118% | $2.54M+14.0% | $2.23M-24.0% | $2.93M-37.4% | $4.68M+77.3% | |
| Revenue by Geography | ||||||
| Non Us | $3.04M-10.9% | $3.41M+13.8% | $2.99M-6.3% | $3.19M+35.6% | $2.36M-30.2% | |
| US | $6.62M+69.9% | $3.89M+1.5% | $3.84M-27.8% | $5.31M-33.9% | $8.03M+51.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does MaxCyte break its business down?
- MaxCyte (MXCT) reports revenue by product across 2 parts — Assay And Other Service Revenue and License. Each is extracted from the segment footnotes and tracked over time.
- Where does MaxCyte's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in MaxCyte's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
